Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav

Nov 19 2012

• By Cathy Dombrowski

Related Content

Dynavax’s Heplisav Heads To Advisory Panel, But Will It Drudge Up Old Safety Issues?

Aug 28 2012

Dynavax Hepatitis B Vaccine Could Get Comparative Post-Market Autoimmunity Assessment

Nov 14 2012

FDA Panel Considers Dynavax’s <em>Heplisav</em> Safety Database Insufficient

Nov 15 2012

GSK Cervarix Clears Landmark FDA Vaccine Committee with Okay for Novel Adjuvant

Sep 09 2009

Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults

Dec 19 2008

Related Companies

Dynavax Technologies Corporation

GSK plc

Additional Topics

United States Advisory Committees Post Market Regulation & Studies Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window